HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $18.43, but opened at $17.02. HUTCHMED shares last traded at $16.93, with a volume of 25,371 shares traded.
Analyst Upgrades and Downgrades
Separately, StockNews.com lowered HUTCHMED from a "buy" rating to a "hold" rating in a report on Monday, November 18th.
Read Our Latest Analysis on HUTCHMED
HUTCHMED Price Performance
The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The firm's 50 day moving average is $18.86 and its 200-day moving average is $18.46.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of HCM. M&G PLC increased its position in HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company's stock valued at $5,345,000 after acquiring an additional 132,333 shares during the period. Renaissance Technologies LLC raised its stake in shares of HUTCHMED by 74.8% during the second quarter. Renaissance Technologies LLC now owns 131,300 shares of the company's stock worth $2,248,000 after purchasing an additional 56,200 shares during the last quarter. Jane Street Group LLC raised its stake in shares of HUTCHMED by 362.2% during the third quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock worth $1,305,000 after purchasing an additional 49,366 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of HUTCHMED by 99.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company's stock worth $952,000 after purchasing an additional 24,245 shares during the period. Finally, Point72 Hong Kong Ltd purchased a new position in HUTCHMED in the 3rd quarter valued at $421,000. 8.82% of the stock is currently owned by institutional investors and hedge funds.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
Featured Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
